Who's Developing What in Global Biopharmaceuticals? : Market Research Report

Who's Developing What in Global Biopharmaceuticals?

Published by: Espicom Healthcare Intelligence

Published: Sep. 25, 2008 - 436 Pages

AFFYMAX: Key Personnel; Company Overview; Milestones; R&D Pipeline; Affymax R&D Pipeline, August 2008; Haematology; Hematide; Other Indications; Innotide; Adeptide; Angiotide; Technology; Agreements; Takeda; Entremed; Nektar; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
AMBIT BIOSCIENCES: Key Personnel; Company Overview; Milestones; R&D Pipeline; Ambit Biosciences R&D Pipeline, August 2008; Oncology; AC220; AC480; AURORA Kinase Inhibitors; BRAF Kinase Inhibitors; JAK2; ABL (T3 151); Technologies; Kinase Profiling Platform; Agreements; Cephalon; bristol-myers squibb; medarex; AstraZeneca; GlaxosmithKline; Roche; Pfizer; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
AMBRX: Key Personnel; Company Overview; Milestones; R&D Pipeline; Human Growth Hormone; ARX201; Technologies; ReCODE Technology; Patents; Agreements; merck serono; Eli Lilly; Roche; merck & Co; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
AMYLIN PHARMACEUTICALS: Key Personnel; Company Overview; Milestones; Marketed Products; metabolism; BYETTA (exenatide, AC2993 (synthetic exendin-4)) injection; SYMLIN (pramlintide acetate) injection; R&D Pipeline; Amylin Pharmaceuticals R&D Pipeline, August 2008; metabolism; Diabetes; Obesity; Discontinued Products; Cardiology; AC3056; AC2592; Agreements; Eli Lilly; Alkermes; Nastech; PsychoGenics; Kelaroo; bioseek; xenome; Johnson & Johnson; Aventis; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
ARANA THERAPEUTICS: Key Personnel; Company Overview; Milestones; R&D Pipeline; Arana Therapeutics R&D Pipeline, August 2008; Autoimmune and Inflammatory Diseases; ART621; PMX53; Oncology; ART104; ART010; ART150; ART140; ART101; ART160; Technologies; Protein Engineering Platforms; Patents; Patent Families - Revenue Generating; Patent Families - Product Development; Agreements; Vegenics; AVEO Pharmaceuticals; CsL Limited; GlaxosmithKline; Centocor; Abbott; EvoGenix Pty; Kyowa Hakko; greenovation biotech; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
ARCA BIOPHARMA: Key Personnel; Company Overview; Milestones; R&D Pipeline; Cardiology; Bucindolol; Agreements; Laboratory Corporation of America Holdings; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
ARIUS RESEARCH: Key Personnel; Company Overview; Milestones; R&D Pipeline; ARIUS Research R&D Pipeline, August 2008; Oncology; CD44 Cancer Stem Cell Program/ARH460-16-2; Trop-2 Signal Transduction Program/AR47A6 4 2; CD59 Complement Inhibitor Program/AR36A36 11 1; CD9 Cancer Stem Cell Program/AR40A746 2 3; AR7BD-33-11A; Others; Technologies; Patents; Agreements; Centro de Immunologia molecular (CImAb); xerion Pharmaceuticals AG; PDL bioPharma; medarex; Oxford biomedica; Genentech; Takeda; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
ARYX THERAPEUTICS: Key Personnel; Company Overview; Milestones; R&D Pipeline; ARYx Therapeutics R&D Pipeline, August 2008; Gastrointestinal; ATI-7505; ATI-24,000; Cardiology; ATI-5923; ATI-2042; Antipsychotic; ATI-9242; metabolism; ATI-20,000; Technologies; Drug Design Technology; Design and Synthesis of Ideal Metabolites; RetroMetabolic Engineering; Evaluation of Metabolism; Patents; Agreements; Procter & Gamble; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
ASTEX THERAPEUTICS: Key Personnel; Company Overview; Milestones; R&D Pipeline; Astex Therapeutics R&D Pipeline, August 2008; Oncology; AT7519; AT9283; AT9311; AT13387; AT13148; Technologies; Drug Discovery Platform; PYRAMID; Patents; Agreements; Technology; Cambridge Crystallographic Data Centre; Daresbury Analytical Research and Technology Service; Global Phasing; Rigaku/MSC; Daylight Chemical Information Systems; Maybridge; Product; Janssen Research Foundation; Aventis; Mitsubishi Pharma; AstraZeneca; Institute of Cancer Research and Cancer Research Technology; The Wellcome Trust, the Institute of Cancer Research, Cancer Research Technology and GlaxoSmithKline; Schering AG; Fujisawa Pharmaceutical; Boehringer Ingelheim; Novartis; Pfizer; University of Newcastle upon Tyne/Cancer Research Technology; GlaxoSmithKline; Janssen Pharmaceutica; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
BIOVEX: Key Personnel; Company Overview; Milestones; R&D Pipeline; BioVex R&D Pipeline, August 2008; Oncology; OncoVEX GM-CSF; Virology; ImmunoVEXHSV2; Patents; Agreements; Wyeth Pharmaceuticals; merck & Co; National Institutes of Health; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
BIOXELL: Key Personnel; Company Overview; Milestones; R&D Pipeline; BioXell R&D Pipeline, August 2008; urology; BXL628/Elocalcitol; Pain Relief; MNAC13; musculoskeletal; BXL093; Inflammation; TREM-1; TREM Programme; BXL746; Technologies; The VD3 platform; mNAC13 Platform; The TREm platform; Agreements; Roche; Lay Line Genomics; merck & Co; Galapagos/Proskelia; Zambon; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
BRUIN PHARMACEUTICALS: Key Personnel; Company Overview; R&D Pipeline; Cardiology; D-4F; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
CELLECTIS: Key Personnel; Company Overview; Milestones; R&D Pipeline; Oncology; Meganucleases targeting p53; Meganucleases targeting XPC; Immunology; Meganuclease targeting IL2RG; Meganuclease targeting RAG1; Patents; Agreements; Artemis Pharmaceuticals; Deltagen; Nucleis; fermentas; Diversa; Regeneron Pharmaceuticals; murinus; Ascenion; Lexicon Genetics; Celliance; xenogen biosciences; Ozgene; biogen Idec; AstraZeneca; shire Pharmaceuticals; Celonic; Genentech; GlaxosmithKline; Laboratoires servier; TransGenic; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
COMBINATORX: Key Personnel; Company Overview; Milestones; R&D Pipeline; CombinatoRx R&D Pipeline, August 2008; Immuno-inflammatory; CRx-102; CRx-139; Pain; CRx-170; Dermatology; CRx-191; CRx-197; metabolism; CRx-401; Other Research Programmes; Technologies; Drug Discovery Platforms; Patents; Agreements; sosei; Accelerate brain Cancer Cure (AbC2); The National Institutes of Allergy and Infectious Diseases; HenKan Pharmaceutical Company; Angiotech Pharmaceuticals; bio*One Capital; fovea Pharmaceuticals sA; Cystic fibrosis foundation Therapeutics; Cure Huntington's Disease Initiative; Charley’s fund/The Nash Avery foundation; spinal muscular Atrophy foundation (smA foundation); sAIC - National Institute of Neurological Disorders and stroke; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
DELTANOID PHARMACEUTICALS: Key Personnel; Company Overview; Milestones; R&D Pipeline; Osteoporosis; 2MD; Agreements; Abbott; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
DIATOS: Key Personnel; Company Overview; Milestones; R&D Pipeline; Diatos R&D Pipeline, August 2008; Oncology; DaunoXome; DTS-301; DTS-201; DTS-108; Technologies; Drug Development Platforms; Agreements; Gilead sciences; macromed; medarex; université catholique de Louvain; Institut Pasteur; servier; OctoPlus Technologies; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
EVOTEC: Key Personnel; Company Overview; Milestones; R&D Pipeline; Evotec R&D Pipeline, August 2008; Central Nervous system; EVT 201; EVT 101; EVT 103; EVT 302; VR1 Antagonist Programme; P2X3 and P2X2/3 Antagonist Programme; B1 antagonists; H3 antagonists; BACE inhibitors; Inflammatory Disease; P2X7 Antagonist Programme; MK2 inhibitors; Oncology; Hsp90 inhibitors; Bcl-2, Bcl-xL and Mcl-1 inhibitors; Technologies; High-throughput screening (HTs) Technology; EVOlution platform; Patents; Agreements; boehringer Ingelheim; Roche; Cure Huntingdon’s Disease Initiative (CHDI); Ono Pharmaceutical; Intermune; Takeda; Interprotein Corporation; Other Research Contracts; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
FIVEPRIME THERAPEUTICS: Key Personnel; Company Overview; Milestones; R&D Pipeline; FivePrime Therapeutics R&D Pipeline, August 2008; Oncology; FP-1039; FPT040; FPA005; FPT069; metabolism; FPT038; Cardiology; FPT033/FPT057; Gastrointestinal; FPT042/FPT046; Immunology; FPT025; Technologies; Drug Discovery Platforms; Agreements; Gene Logic; biosite; boehringer Ingelheim; Centocor/Johnson & Johnson; Pfizer; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
GENMAB A/S: Key Personnel; Company Overview; Milestones; R&D Pipeline; Genmab R&D Pipeline, August 2008; Oncology; HuMax-CD4 (zanolimumab); HuMax-CD20 (ofatumumab); HuMax-EGFr (zalutumumab); R1507; HuMax-IL8; HuMax-CD38; HuMax-CD32b; Autoimmune/Anti-inflammatory; HuMax-CD20 (ofatumumab); AMG 714; HuMax-IL8; HuMax-TAC; Neurology; HuMax-CD20 (ofatumumab); Dermatology; HuMax-IL8; HuMax-TAC; Respiratory; Roche 4; Virology; HuMax-HepC; Transplant Rejection; HuMax-TAC; undisclosed Indications; Roche 2; Roche 3; Technologies; Antibody Discovery Engine; Antibody Centre of Excellence; UniBody; Patents; Agreements; Amgen; ACE biosciences; bionomics; Cytokine Pharmasciences; Ganymed Pharmaceuticals; GlaxosmithKline; medarex; merck serono; Roche; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
IDENIX PHARMACEUTICALS: Key Personnel; Company Overview; Milestones; Marketed Products; R&D Pipeline; Idenix Pharmaceuticals R&D Pipeline, August 2008; Virology; IDX184; IDX899; IDX375; IDX136/IDX316 Macrocyclic Protease Inhibitors; Discontinued Products; Valopicitabine/NM283; Patents; Agreements; metabasis Therapeutics; Novartis Pharma; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
IKARIA: Key Personnel; Company Overview; Milestones; Marketed Products; R&D Pipeline; Ikaria R&D Pipeline, August 2008; Cardiology; INOMax; IK-1001; Immunology; Covox; Other Research Programmes; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
INFINITY PHARMACEUTICALS: Key Personnel; Company Overview; Milestones; R&D Pipeline; Infinity Pharmaceuticals R&D Pipeline, August 2008; Oncology; Retaspimycin; IPI-493; IPI-926; Bcl-2 Protein Inhibitors; Technologies; Diversity Oriented synthesis Technologies; Patents; Agreements; medImmune/AstraZeneca; Novartis; Amgen; Johnson & Johnson; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
INTERCYTEX: Key Personnel; Company Overview; Milestones; R&D Pipeline; Intercytex R&D Pipeline, August 2008; Dermatology; ICX-PRO (cyzact); VAVELTA; ICX-TRC; ICX-SKN; Technologies; Agreements; baxter Healthcare; The Automation Partnership; Armed forces Institute of Regenerative medicine; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
IRONWOOD PHARMACEUTICALS: Key Personnel; Company Overview; Milestones; R&D Pipeline; Ironwood Pharmaceuticals R&D Pipeline, August 2008; Gastrointestinal; MD-1100/linaclotide; Cardiology; MD-0727; Agreements; forest Laboratories; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
KAI PHARMACEUTICALS: Key Personnel; Company Overview; Milestones; R&D Pipeline; KAI Pharmaceuticals, August 2008; Cardiology; KAI-9803; KAI-1455; Pain management; KAI-1678; Gamma PKC; Ophthalmology; Beta PKC; Inflammatory Disease; Theta PKC Inhibition; Agreements; sankyo; bristol-myers squibb; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
KALYPSYS: Key Personnel; Company Overview; Milestones; R&D Pipeline; Kalypsys R&D Pipeline, August 2008; metabolism; KD3010; KD3020; Pain; KD7040; Oncology; KD5170; Technologies; Agreements; merck & Co; CV Therapeutics; Los Alamos National Laboratory; National Institutes of Health; NovImmune; Eidogen-sertanty; Alcon; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
KEREOS: Key Personnel; Company Overview; Milestones; R&D Pipeline; Kereos R&D Pipeline, August 2008; Oncology; KI-0001; KI-100X; KM-4419; Cardiology; KI-0002; KI-1004; Technologies; Ligand-Targeted Emulsion Technologies; Agreements; Philips; Lantheus medical Imaging (bristol-myers squibb medical Imaging); Dow Chemical; Washington university; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
MICROMET: Key Personnel; Company Overview; Milestones; R&D Pipeline; Micromet R&D Pipeline, August 2008; BiTE Antibody Only Pipeline; Oncology; MT103/MEDI-538; Adecatumumab (MT201); MT293 (D93/TRC093); MT110; MT111; MT228 (MORAb-028); bscEphA2xCD3; muS110; Antibodies targeting CD33 and MCSP; Inflammatory/Autoimmune Diseases; MT203; MT204; Technologies; biTE (bispecific T-Cell Engagers) Technology; single Chain Antibodies; Patents; Agreements; Enzon Pharmaceuticals; Abbott, Alligator bioscience Ab, Haptogen and A N Other; Cambridge Antibody Technology (CAT); EsbATech AG; medImmune; serono; EvoGenix Pty; Novuspharma spA; TRACON Pharmaceuticals; morphotek; Nycomed; university of southern California; Applied molecular Evolution/Eli Lilly; Arizeke Pharmaceuticals; Antigenics; Viventia barbados; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
MOLECULAR INSIGHT PHARMACEUTICALS: Key Personnel; Company Overview; Milestones; R&D Pipeline; Molecular Insight R&D Pipeline, August 2008; Oncology; Azedra; Onalta; Solazed; Trofex; Cardiology; Zemiva; MIP-190; Neurology; MIP-170D; Technologies; ultratrace Technology; sAAC Technology; sAACQ Technology; Nanotrace Discovery; Patents; Agreements; bayer schering Pharma; Novartis Pharma; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
NEUROMED PHARMACEUTICALS: Key Personnel; Company Overview; Milestones; R&D Pipeline; Neuromed Pharmaceuticals Pipeline, August 2008; Pain; NMED-160; NMED-1077; Others; Other Indications; Agreements; merck & Co; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
NOVEXEL: Key Personnel; Company Overview; Milestones; R&D Pipeline; Novexel R&D Pipeline, August 2008; Antibacterial; NXL103; NXL101; NXL104; NXL105; Antifungal; NXL201; Agreements; Indevus Pharmaceuticals; forest Laboratories; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
NPS PHARMACEUTICALS: Key Personnel; Company Overview; Milestones; R&D Pipeline; NPS Pharmaceuticals R&D Pipeline, August 2008; Gastrointestinal; GATTEX; musculoskeletal; PREOS/Preotact; calcilytics; Central Nervous system; NPSP156; metabolism; NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection); Renal; Cinacalcet HCl; Patents; Agreements; Amgen; Kirin Pharma; Nycomed; DRI Capital; GlaxosmithKline; Janssen; AstraZeneca; Ortho-mcNeil Pharmaceuticals; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
OPTIMER PHARMACEUTICALS: Key Personnel; Company Overview; Milestones; R&D Pipeline; Optimer Pharmaceuticals R&D Pipeline, August 2008; Antibacterial; OPT-80; Prulifloxacin (OPT-99); OPT-1068/CEM-101; musculoskeletal; OPT-88; Oncology; OPT-822/OPT-821; Technologies; Drug Discovery Platform; Patents; Agreements; C&O Pharmaceutical Technology (Holdings); Par Pharmaceutical; biocon; Nippon shinyaku; sloan-Kettering Institute for Cancer Research; Cempra Pharmaceuticals; The scripps Research Institute; Inc Research; National Institute of Allergy and Infectious Diseases; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
PALATIN TECHNOLOGIES: Key Personnel; Company Overview; Milestones; R&D Pipeline; Palatin Technologies R&D Pipeline, August 2008; Cardiology; Bremelanotide; PL-6983; Natriuretic Receptor Compounds/PL-3994; metabolism; Melanocortin-based Therapeutics; Imaging/Diagnosis; NeutroSpec; Technologies; Drug Development Platforms; MIDAS Drug Development Platform; NeutroSpec; Patents; Agreements; AstraZeneca; mallinckrodt; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
PHARMAMAR: Key Personnel; Company Overview; Milestones; R&D Pipeline; PharmaMar R&D Pipeline, August 2008; Oncology; Yondelis (trabectedin); Aplidin (plitidepsin); PM02734; Kahalalide F; Zalypsis; Thiocoraline; Variolins; Lamellarins; Dermatology; Kahalalide F; Agreements; Johnson & Johnson; Innovex; swedish Orphan International; Genesis Pharma; Cenit-Nanopharma Consortium; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
PRANA BIOTECHNOLOGY: Key Personnel; Company Overview; Milestones; R&D Pipeline; Prana Biotechnology R&D Pipeline, August 2008; Central Nervous system; PBT2; Drug Candidate; Amyloid-inhibiting compounds; Immunotherapy; MAbs against Abeta; Oncology; PBT1/others; Ophthalmology; MPAC Compounds; Discontinued Products; Central Nervous system; PBT1 (Clioquinol); Patents; Agreements; schering AG; Australian Industry Research and Development board; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
REPLIDYNE: Key Personnel; Company Overview; Milestones; R&D Pipeline; Replidyne R&D Pipeline, August 2008; Antibacterial; Faropenem medoxomil; REP3123/REP8839; DNA Replication Inhibitors Programme; Patents; Agreements; forest Laboratories; Asubio Pharma; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
S*BIO: Key Personnel; Company Overview; Milestones; R&D Pipeline; Clinical Trials; HDAC; Kinase Programme; S*BIO R&D Pipeline, 2008; Technology; Agreements; A*sTAR; Genome Institute of singapore; Karolinska Institutet; National university Hospital, singapore; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
SOSEI: Key Personnel; Company Overview; Milestones; R&D Pipeline; Sosei R&D Pipeline, August 2008; Respiratory system; NVA237; QVA149; Oncology; AD923; Central Nervous system; AD337; SD118; Inflammation and Immunology; SD726; SD208; Women’s Healthcare; SOH-075; Agreements; mundipharma; sandoz; CombinatoRx; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
SPEEDEL PHARMACEUTICALS: Key Personnel; Company Overview; Milestones; R&D Pipeline; Speedel R&D Pipeline, August 2008; Cardiology; SPP100 (aliskiren,Tekturna, Rasilez); SPP200 (pegmusirudin); SPP301 (avosentan); SPP600; SPP635; SPP676; SPP800 Series; SPP1100 Series; SPP2000 Series; Agreements; Locus Pharmaceuticals; Novartis; Roche; Abbott Laboratories; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
SYNTA PHARMACEUTICALS: Key Personnel; Company Overview; Milestones; R&D Pipeline; Synta Pharmaceuticals R&D Pipeline, August 2008; Oncology; STA-4783 (elesclomol); STA-9090; STA-9584; STA-5312; Inflammatory Disease; STA-5326 (apilimod mesylate); Crohn’s Disease; Rheumatoid Arthritis; Common Variable Immunodeficiency; Psoriasis; CRAC ion channel inhibitor; Technologies; Chemical Library; screening Assays; In vivo Testing Capabilities; Chemistry Capabilities; Target Elucidation; Patents; Agreements; GlaxosmithKline; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
SYNTAXIN: Key Personnel; Company Overview; Milestones; R&D Pipeline; Syntaxin R&D Pipeline, August 2008; Pain; Un-named Product; Respiratory; SYN187; Other; Endocrinology Products; Obesity Products; Nerve Disorder Products; Agreements; Allergan; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
TAKARA BIO: Key Personnel; Company Overview; Milestones; R&D Pipeline; Oncology; HSV-TK gene therapies; T-cell receptor (TCR) gene therapy; Cancer Immunotherapy; Cancer Immunity Reconstruction Therapy; Virology; VRX496; MazF Gene Therapy; Technologies; Research Reagents and scientific Instruments; Contract Research services; Agreements; InVivoscribe Technologies; memorial sloan-Kettering Cancer Center; Peter macCallum Cancer Centre; Green Cross Corporation; New England biolabs; Transgenomic; Kemp biotechnologies; Tianjin medical university; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
THERAVANCE: Key Personnel; Company Overview; Milestones; R&D Pipeline; Theravance R&D Pipeline, August 2008; Antibacterial; Telavancin; TD-1792; Respiratory; GW642444; GW685698; GSK159797; GSK1160724; GSK656398; GSK961081; Gastrointestinal; TD-5108; TD-2749; TD-6301; Patents; Agreements; Astellas; GlaxosmithKline; AstraZeneca; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
TRANZYME PHARMA: Key Personnel; Company Overview; Milestones; R&D Pipeline; Tranzyme Pharma R&D Pipeline, August 2008; Gastrointestinal; TZP-101; TZP-102; TZP-201; TZP-301; Technologies; Drug Discovery Platform; Macrocyclic Template Chemistry (MATCH); Patents; Agreements; Neokimia/Trimeris; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
TRIMERIS: Key Personnel; Company Overview; Milestones; Marketed Products; Virology; FUZEON; R&D Pipeline; Virology; FUZEON; TRI-1144; Patents; Agreements; Roche; Array biopharma; Neokimia/Tranzyme; Chembridge Research Laboratories; New york blood Center; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
TRUBION PHARMACEUTICALS: Key Personnel; Company Overview; Milestones; R&D Pipeline; Trubion Pharmaceuticals R&D Pipeline, August 2008; Autoimmune/Inflammatory Diseases; TRU-015; SBI-087; Oncology; TRU-015; TRU-016; Technologies; Product Engine; Patents; Agreements; Wyeth; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
VIROPHARMA: Key Personnel; Company Overview; Milestones; Marketed Products; Antibacterial; Vancocin; R&D Pipeline; ViroPharma R&D Pipeline, August 2008; Virology; Maribavir (CAMVIA); CDI Programme; Anti-inflammatory; C1 inhibitor (human); Discontinued Products; Virology; Picovir (Pleconaril); Hepatitis C Candidates; HCV371; HCV-086; HCV-796; Patents; Agreements; GlaxosmithKline; sanofi-synthélabo/sanofi-aventis; schering-Plough; Eli Lilly; Wyeth; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
WILEX: Key Personnel; Company Overview; Milestones; R&D Pipeline; WILEX R&D Pipeline, August 2008; Oncology; WX-G250 and WX-G250RIT (RENCAREX); WX-UK1; K931; WX-671 (MESUPRON); CA9-SCAN (REDECTANE); WX-77X Series; Patents; Agreements; Centocor; bayer; Vu university medical Center Amsterdam; fox Chase Cancer Center; Esteve; IbA molecular; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
XENCOR: Key Personnel; Company Overview; Milestones; R&D Pipeline; Xencor R&D Pipeline, August 2008; Inflammatory Disease; XPro1595; Oncology; XmAb2513; Oncology/Inflammatory Disease; XmAb5574; XmAb5871; XmAb5485; Technologies; Protein Design Automation; xPro; XmAb technology; ImmunoPDA; Patents; Agreements; Caltech; Torrey mesa Research Institute; Protein Design Labs; Eli Lilly; Genentech; Chugai Pharmaceutical; Centocor; medImmune; Roche; boehringer Ingelheim; Human Genome sciences; Key Financial Data; Appraisal & Evaluation; Platform, Pipeline, Products; Corporate Environment
ESPICOM ANALYSIS: Winners & Losers; Biopharmaceutical Company R&D Pipelines; Phase III Drug Candidates; Phase III Drug Candidates; Methodology; Company Ratings

Abstract

A critical assessment of 50 leading companies, their research, products, partners and performance.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Who's Developing What in Global Biopharmaceuticals?

Table of Contents

Abstract